262 results
Page 2 of 14
8-K
EX-99.1
qa3wkp89nfvkdxep
13 Sep 22
Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes
4:05pm
8-K
EX-99.1
8bgvs g8z
28 Jul 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
tnprx8sq
14 Jun 22
Other Events
7:30am
8-K
EX-99.1
1m6z j4ei0rnv2pcsb6h
28 Apr 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
ow366aq16jjfirz
5 Apr 22
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
4:16pm
8-K
EX-99.1
uriol
4 Apr 22
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
7:35am
8-K
EX-99.1
bjepvflvva390kprrt
10 Feb 22
Results of Operations and Financial Condition
8:10am
8-K
EX-99.1
1f9j89
10 Jan 22
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
7:01am
8-K
EX-99.1
knl c97dzbkwy70x
4 Jan 22
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
4:16pm
8-K
EX-99.1
6ay5gh2mm
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
7q2lwtp
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
EX-99.2
mkraxc n2op
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
EX-99.1
p28ob qqg4ws
3 Aug 21
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights
8:10am
8-K
0l9 rzecknpjokjut
3 Aug 21
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights
8:10am